| scholarly article | Q13442814 |
| P50 | author | Stephane Loyau | Q57067993 |
| Martine Jandrot-Perrus | Q57068013 | ||
| Philippe Billiald | Q59706136 | ||
| P2093 | author name string | P Mangin | |
| M Zahid | |||
| B Hechler | |||
| C Gachet | |||
| P2860 | cites work | Cloning and expression of the platelet-specific collagen receptor glycoprotein VI | Q22254152 |
| Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain | Q24308747 | ||
| Platelet activation and signal transduction by convulxin, a C-type lectin from Crotalus durissus terrificus (tropical rattlesnake) venom via the p62/GPVI collagen receptor | Q24321786 | ||
| A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion | Q24621493 | ||
| Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo | Q24669536 | ||
| Expression and function of the mouse collagen receptor glycoprotein VI is strictly dependent on its association with the FcRgamma chain | Q28145083 | ||
| The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcalphaR and the natural killer receptors | Q28145360 | ||
| Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events | Q28195656 | ||
| Analysis of the interaction of platelet collagen receptor glycoprotein VI (GPVI) with collagen. A dimeric form of GPVI, but not the monomeric form, shows affinity to fibrous collagen | Q28204718 | ||
| Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial | Q28209556 | ||
| Association of Fyn and Lyn with the proline-rich domain of glycoprotein VI regulates intracellular signaling | Q28214216 | ||
| A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets | Q28248776 | ||
| A compound heterozygous mutation in glycoprotein VI in a patient with a bleeding disorder | Q28249764 | ||
| GPVI and integrin alphaIIb beta3 signaling in platelets | Q28267414 | ||
| Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen | Q28364081 | ||
| Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinase | Q45016543 | ||
| The immunoadhesin glycoprotein VI-Fc regulates arterial remodelling after mechanical injury in ApoE-/- mice | Q46530171 | ||
| GPVI-deficient mice lack collagen responses and are protected against experimentally induced pulmonary thromboembolism | Q46684669 | ||
| Gain- and loss-of-function mutants confirm the importance of apical residues to the primary interaction of human glycoprotein VI with collagen | Q46888768 | ||
| Glycoprotein (GP) VI dimer as a major collagen-binding site of native platelets: direct evidence obtained with dimeric GPVI-specific Fabs | Q47680746 | ||
| Structural basis for the platelet-collagen interaction: the smallest motif within collagen that recognizes and activates platelet Glycoprotein VI contains two glycine-proline-hydroxyproline triplets. | Q48697081 | ||
| Impact of glycoprotein VI and platelet adhesion on atherosclerosis--a possible role of fibronectin. | Q50554991 | ||
| An acquired inhibitor to the GPVI platelet collagen receptor in a patient with lupus nephritis. | Q51778345 | ||
| EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism: potential impact on atherothrombosis. | Q51799143 | ||
| Anti-glycoprotein VI monoclonal antibodies directly aggregate platelets independently of FcgammaRIIa and induce GPVI ectodomain shedding. | Q51806436 | ||
| Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI. | Q51936883 | ||
| The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion | Q52550457 | ||
| Absence of collagen-induced platelet activation caused by compound heterozygous GPVI mutations | Q55670474 | ||
| Soluble Glycoprotein VI Is Raised in the Plasma of Patients With Acute Ischemic Stroke | Q57306100 | ||
| Sandwich Immunoassay for Soluble Glycoprotein VI in Patients with Symptomatic Coronary Artery Disease | Q57735718 | ||
| Chimeric Fc Receptors Identify Ligand Binding Regions in Human Glycoprotein VI | Q58861428 | ||
| Pathologic shear triggers shedding of vascular receptors: a novel mechanism for down-regulation of platelet glycoprotein VI in stenosed coronary vessels | Q59281453 | ||
| Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa | Q59281458 | ||
| Molecular priming of Lyn by GPVI enables an immune receptor to adopt a hemostatic role | Q30157042 | ||
| Vav1 and vav3 have critical but redundant roles in mediating platelet activation by collagen. | Q30163810 | ||
| Synergism between platelet collagen receptors defined using receptor-specific collagen-mimetic peptide substrata in flowing blood | Q30495037 | ||
| Deficiency of P62, a putative collagen receptor, in platelets from a patient with defective collagen‐induced platelet aggregation | Q33350522 | ||
| Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. | Q33360832 | ||
| The Fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats | Q33374356 | ||
| Diverging signaling events control the pathway of GPVI down-regulation in vivo | Q33374637 | ||
| A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex | Q33379144 | ||
| Compromised ITAM-based platelet receptor function in a patient with immune thrombocytopenic purpura. | Q33379632 | ||
| Complementary roles of platelets and coagulation in thrombus formation on plaques acutely ruptured by targeted ultrasound treatment: a novel intravital model | Q33382490 | ||
| Single domain antibodies against the collagen signalling receptor glycoprotein VI are inhibitors of collagen induced thrombus formation | Q33449506 | ||
| Design and humanization of a murine scFv that blocks human platelet glycoprotein VI in vitro | Q33475093 | ||
| A humanized glycoprotein VI (GPVI) mouse model to assess the antithrombotic efficacies of anti-GPVI agents. | Q34124802 | ||
| Antiplatelet therapy: in search of the 'magic bullet'. | Q35550212 | ||
| Rap1-Rac1 circuits potentiate platelet activation | Q35683204 | ||
| The influence of N-linked glycosylation on the function of platelet glycoprotein VI | Q35848393 | ||
| Laminin stimulates spreading of platelets through integrin alpha6beta1-dependent activation of GPVI. | Q35848605 | ||
| Platelet collagen receptors and coagulation. A characteristic platelet response as possible target for antithrombotic treatment | Q36205337 | ||
| A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo | Q36370457 | ||
| Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice | Q36376147 | ||
| The Modifier of hemostasis (Mh) locus on chromosome 4 controls in vivo hemostasis of Gp6-/- mice | Q36407118 | ||
| Platelet glycoprotein VI-related clinical defects | Q36957977 | ||
| Non-invasive molecular imaging of fibrosis using a collagen-targeted peptidomimetic of the platelet collagen receptor glycoprotein VI | Q37188547 | ||
| Distinct spatio-temporal Ca2+ signaling elicited by integrin alpha2beta1 and glycoprotein VI under flow. | Q37372846 | ||
| Diagnostic and therapeutic potentials of platelet glycoprotein VI. | Q37736347 | ||
| Reperfusion therapy in acute cerebrovascular syndrome | Q37811859 | ||
| Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke | Q37875489 | ||
| The evolution of antiplatelet therapy in cardiovascular disease | Q37900470 | ||
| Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans | Q38492137 | ||
| Monomeric (glycine-proline-hydroxyproline)10 repeat sequence is a partial agonist of the platelet collagen receptor glycoprotein VI. | Q42260383 | ||
| Activation-independent, antibody-mediated removal of GPVI from circulating human platelets: development of a novel NOD/SCID mouse model to evaluate the in vivo effectiveness of anti-human platelet agents | Q42741745 | ||
| Structural basis for platelet antiaggregation by angiotensin II type 1 receptor antagonist losartan (DuP-753) via glycoprotein VI. | Q43160985 | ||
| Expression of platelet glycoprotein VI is associated with transient ischemic attack and stroke | Q43290763 | ||
| Evidence for cross-talk between glycoprotein VI and Gi-coupled receptors during collagen-induced platelet aggregation. | Q43627737 | ||
| Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody | Q44592655 | ||
| Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood | Q44620766 | ||
| Principal role of glycoprotein VI in alpha2beta1 and alphaIIbbeta3 activation during collagen-induced thrombus formation | Q44961840 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2418-2427 | |
| P577 | publication date | 2012-12-01 | |
| P1433 | published in | Journal of Thrombosis and Haemostasis | Q6296004 |
| P1476 | title | The future of glycoprotein VI as an antithrombotic target | |
| P478 | volume | 10 |
| Q41628315 | ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions. |
| Q37526189 | Alteration of platelet GPVI signaling in ST-elevation myocardial infarction patients demonstrated by a combination of proteomic, biochemical, and functional approaches. |
| Q32177061 | Anti-GPVI Fab SAR264565 effectively blocks GPVI function in ex vivo human platelets under arterial shear in a perfusion chamber |
| Q38543308 | Antiplatelet drugs: which targets for which treatments? |
| Q38990156 | Basic mechanisms of platelet receptor shedding |
| Q38983805 | Clinical significance of receptor shedding-platelet GPVI as an emerging diagnostic and therapeutic tool. |
| Q28066352 | Cross-Linking GPVI-Fc by Anti-Fc Antibodies Potentiates Its Inhibition of Atherosclerotic Plaque- and Collagen-Induced Platelet Activation |
| Q47215330 | Current and future antiplatelet therapies: emphasis on preserving haemostasis |
| Q40450129 | Decreased levels of platelet-derived soluble glycoprotein VI detected prior to the first diagnosis of coronary artery disease in HIV-positive individuals. |
| Q41578105 | Differential Inhibition of Human Atherosclerotic Plaque-Induced Platelet Activation by Dimeric GPVI-Fc and Anti-GPVI Antibodies: Functional and Imaging Studies |
| Q36091308 | Fibrin activates GPVI in human and mouse platelets |
| Q90480558 | Glycoprotein VI in securing vascular integrity in inflamed vessels |
| Q54328623 | Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. |
| Q38969861 | Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies |
| Q52730893 | Immobilized fibrinogen activates human platelets through glycoprotein VI. |
| Q33624852 | Pannexin- and Connexin-Mediated Intercellular Communication in Platelet Function. |
| Q39449769 | Platelet "first responders" in wound response, cancer, and metastasis |
| Q34294719 | Platelets and cancer: a casual or causal relationship: revisited. |
| Q52729803 | Post-translational modification of type IV collagen with 3-hydroxyproline affects its interactions with glycoprotein VI and nidogens 1 and 2. |
| Q38206848 | Primary haemostasis: newer insights. |
| Q35846181 | Regulation of Early Steps of GPVI Signal Transduction by Phosphatases: A Systems Biology Approach |
| Q57280930 | Role of platelets and platelet receptors in cancer metastasis |
| Q33689745 | Targeting GPVI as a novel antithrombotic strategy |
| Q43692419 | The Cape Chacma baboon is not suitable for evaluating human targeted anti-GPVI agents |
| Q26768149 | The integrin-collagen connection--a glue for tissue repair? |
Search more.